December 10, 2018 - 1:01 a.m.
Gilead Sciences Names Daniel O’Day Chairman and Chief Executive Officer
Printer Friendly Version 
December 04, 2018 - 8:31 a.m.
China National Medical Products Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection
Printer Friendly Version 
December 04, 2018 - 8:31 a.m.
China’s National Medical Products Administration Approves Harvoni® (Ledipasvir/Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Genotype 1-6
Printer Friendly Version 
December 03, 2018 - 8:02 p.m.
Kite Announces Updated Data From ZUMA-3 Study of KTE-X19 in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Printer Friendly Version 
December 02, 2018 - 12:05 p.m.
Kite Announces Two-Year Data for Yescarta® (Axicabtagene Ciloleucel) in Patients With Refractory Large B-Cell Lymphoma
Printer Friendly Version 
November 18, 2018 - 10:01 p.m.
China National Medical Products Administration (NMPA) Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for Chronic Hepatitis B Virus (HBV) Infection
Printer Friendly Version 
November 12, 2018 - 5:02 p.m.
Gilead Sciences to Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27
Printer Friendly Version 
November 09, 2018 - 8:01 a.m.
Gilead Announces Positive Phase 2 Results for GS-9674 in Primary Sclerosing Cholangitis (PSC) at The Liver Meeting® 2018
Printer Friendly Version 
November 09, 2018 - 8:01 a.m.
Gilead Presents Data From Nonalcoholic Steatohepatitis (NASH) Development Program for Advanced Fibrosis at The Liver Meeting® 2018
Printer Friendly Version 
November 09, 2018 - 8:01 a.m.
Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018
Printer Friendly Version 
November 01, 2018 - 9:02 a.m.
Gilead to Present Latest Scientific Research in Hematologic Malignancies and Solid Tumors at ASH 2018
Printer Friendly Version 
October 31, 2018 - 8:31 a.m.
Gilead Sciences and Tango Therapeutics Announce Strategic Collaboration to Develop Next-Generation Targeted Immuno-Oncology Therapies
Printer Friendly Version 
October 30, 2018 - 6:37 a.m.
Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy
Printer Friendly Version 
October 25, 2018 - 4:03 p.m.
Gilead Sciences Announces Fourth Quarter 2018 Dividend
Printer Friendly Version 
October 25, 2018 - 4:02 p.m.
Gilead Sciences Announces Third Quarter 2018 Financial Results
Printer Friendly Version 
October 22, 2018 - 1:16 p.m.
Positive Trial Results with Filgotinib in Psoriatic Arthritis and Ankylosing Spondylitis Both Published in The Lancet
Printer Friendly Version 
October 20, 2018 - 6:32 p.m.
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting
Printer Friendly Version 
October 11, 2018 - 4:06 p.m.
Gilead Sciences to Release Third Quarter 2018 Financial Results on Thursday, October 25, 2018
Printer Friendly Version 
October 11, 2018 - 3:24 p.m.
Gilead to Present Wide-Ranging New Data on Treatment and Diagnosis of Liver Diseases at The Liver Meeting® 2018
Printer Friendly Version 
October 03, 2018 - 8:31 a.m.
Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy
Printer Friendly Version 
October 02, 2018 - 8:32 a.m.
Kite and HiFiBiO Therapeutics Announce a Research Collaboration to Develop Technology for the Potential Discovery of Neoantigen-Reactive T Cell Receptors (TCRs) for the Treatment of Cancer
Printer Friendly Version 
September 24, 2018 - 8:31 a.m.
Gilead Subsidiary to Launch Authorized Generics of Epclusa® (Sofosbuvir/Velpatasvir) and Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C
Printer Friendly Version 
September 12, 2018 - 8:32 a.m.
Gilead Sciences and Precision BioSciences Announce Collaboration to Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing
Printer Friendly Version 
September 11, 2018 - 4:06 p.m.
Gilead and Galapagos Announce Filgotinib Meets Primary and All Key Secondary Endpoints in First Phase 3 Study in Rheumatoid Arthritis
Printer Friendly Version 
September 06, 2018 - 1:01 a.m.
Gilead and Galapagos Announce TORTUGA Phase 2 Study of Filgotinib in Ankylosing Spondylitis Achieves Primary Endpoint
Printer Friendly Version 
September 04, 2018 - 4:06 p.m.
Gilead Enters Licensing Agreement With Trianni for Use of Trianni Transgenic Human Monoclonal Antibody Discovery Platform
Printer Friendly Version 
August 30, 2018 - 4:02 p.m.
Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 12
Printer Friendly Version 
August 28, 2018 - 5:01 p.m.
Gilead Sciences Appoints Laura Hamill as Executive Vice President, Worldwide Commercial Operations
Printer Friendly Version 
August 27, 2018 - 6:35 a.m.
Yescarta® (Axicabtagene Ciloleucel) Receives European Marketing Authorization for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy
Printer Friendly Version 
August 14, 2018 - 5:01 p.m.
Gilead Sciences Announces Executive Promotions
Printer Friendly Version 
August 06, 2018 - 6:10 a.m.
China National Drug Administration Approves Gilead’s Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), a Single Tablet Regimen for the Treatment of HIV-1 Infection
Printer Friendly Version 
July 25, 2018 - 4:03 p.m.
Gilead Sciences Announces Third Quarter 2018 Dividend
Printer Friendly Version 
July 25, 2018 - 4:02 p.m.
Gilead Sciences Announces Second Quarter 2018 Financial Results
Printer Friendly Version 
July 25, 2018 - 4:01 p.m.
Gilead Sciences Announces CEO John F. Milligan to Step Down
Printer Friendly Version 
July 24, 2018 - 8:02 a.m.
Gilead Announces New Data on the Impact of Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Pre-Exposure Prophylaxis (PrEP) on the Number of HIV Diagnoses in the United States
Printer Friendly Version 
July 19, 2018 - 8:30 a.m.
Kite and Gadeta Announce Strategic Collaboration to Advance Gamma Delta T Cell Receptor Technology for Solid Tumors
Printer Friendly Version 
July 13, 2018 - 4:09 p.m.
Gilead Sciences to Release Second Quarter 2018 Financial Results on Wednesday, July 25, 2018
Printer Friendly Version 
July 09, 2018 - 4:30 p.m.
Michael Amoroso to Join Kite as Senior Vice President and Head of Worldwide Commercial, Cell Therapy
Printer Friendly Version 
June 29, 2018 - 7:54 a.m.
European CHMP Adopts Positive Opinion for Yescarta® (axicabtagene ciloleucel) for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy
Printer Friendly Version 
June 25, 2018 - 8:04 a.m.
European Commission Grants Marketing Authorization for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection
Printer Friendly Version 
June 11, 2018 - 8:32 a.m.
Gilead Sciences’ Chief Scientific Officer John McHutchison Appointed Officer of the Order of Australia
Printer Friendly Version 
June 05, 2018 - 2:07 p.m.
Hookipa and Gilead Enter into a Collaboration and License Agreement to Develop Immunotherapies Against HIV and Hepatitis B
Printer Friendly Version 
June 04, 2018 - 5:00 p.m.
Gilead Sciences Announces Leadership Changes in Corporate Development and Strategy
Printer Friendly Version 
June 04, 2018 - 9:02 a.m.
Kite Announces Initial Results From a Phase 1 Study of T Cell Receptor (TCR) Cell Therapy in HPV-16-Positive Solid Tumors
Printer Friendly Version 
June 04, 2018 - 9:02 a.m.
Kite Announces New Data Analyses for CAR T Therapy in Patients with Blood Cancers at the 2018 American Society of Clinical Oncology Meeting
Printer Friendly Version 
May 30, 2018 - 4:03 p.m.
Gilead and Galapagos Announce Results With Filgotinib in the Phase 2 Equator Study in Psoriatic Arthritis and Progression Into Phase 3 for the Selection Study in Ulcerative Colitis
Printer Friendly Version 
May 30, 2018 - 4:03 p.m.
Gilead Sciences to Present at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13
Printer Friendly Version 
May 30, 2018 - 1:01 a.m.
China Drug Administration Approves Epclusa® (Sofosbuvir/Velpatasvir), Gilead’s Pan-Genotypic Treatment for Chronic Hepatitis C Virus Infection
Printer Friendly Version 
May 23, 2018 - 4:02 p.m.
Gilead Sciences to Present at the Jefferies 2018 Healthcare Conference on Wednesday, June 6
Printer Friendly Version 
May 15, 2018 - 10:58 a.m.
U.S. Food and Drug Administration Approves Expanded Indication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents
Printer Friendly Version 
May 15, 2018 - 8:32 a.m.
Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline
Printer Friendly Version 
May 09, 2018 - 4:31 p.m.
Harish Manwani Joins Gilead Sciences’ Board of Directors
Printer Friendly Version 
May 08, 2018 - 9:02 a.m.
Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 16
Printer Friendly Version 
May 01, 2018 - 4:03 p.m.
Gilead Sciences Announces Second Quarter 2018 Dividend
Printer Friendly Version 
May 01, 2018 - 4:03 p.m.
Gilead Sciences Announces First Quarter 2018 Financial Results
Printer Friendly Version 
April 30, 2018 - 4:06 p.m.
Gilead and Verily Announce Scientific Collaboration to Identify and Understand Immunological and Molecular Drivers of Inflammatory Diseases
Printer Friendly Version 
April 27, 2018 - 6:37 a.m.
European CHMP Adopts Positive Opinion for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide)
Printer Friendly Version 
April 17, 2018 - 5:02 p.m.
Gilead Sciences to Release First Quarter 2018 Financial Results on Tuesday, May 1, 2018
Printer Friendly Version 
April 13, 2018 - 10:15 a.m.
Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis at The International Liver Congress™ 2018
Printer Friendly Version 
March 12, 2018 - 9:02 a.m.
Gilead Sciences’ Norbert Bischofberger, PhD, to Step Down; John McHutchison, MD, Appointed Chief Scientific Officer and Andrew Cheng, MD, PhD, Appointed Chief Medical Officer
Printer Friendly Version 
March 05, 2018 - 4:01 p.m.
Gilead Presents Data From Phase 3 Study Evaluating Women Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) From a Boosted Protease Inhibitor-Based Regimen or Boosted Elvitegravir-Containing Regimen
Printer Friendly Version 
March 05, 2018 - 12:08 p.m.
Gilead Presents Results from Phase 3 Study Evaluating Patients Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) from Regimen Containing Abacavir, Dolutegravir and Lamivudine
Printer Friendly Version 
March 04, 2018 - 4:20 p.m.
Gilead Announces Data from New Preclinical Study Evaluating a Combination of an Investigational TLR7 Agonist and an Investigational HIV Envelope Targeting Antibody in SHIV-Infected, Virally Suppressed Monkeys
Printer Friendly Version 
February 22, 2018 - 5:01 p.m.
Gilead Sciences Announces Senior Management Change
Printer Friendly Version 
February 22, 2018 - 7:01 a.m.
Kite, a Gilead Company, and Sangamo Therapeutics Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for the Treatment of Cancer
Printer Friendly Version 
February 08, 2018 - 4:02 p.m.
Gilead Sciences to Present at the RBC Capital Markets 2018 Global Healthcare Conference on Wednesday, February 21
Printer Friendly Version 
February 07, 2018 - 2:22 p.m.
U.S. Food and Drug Administration Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection
Printer Friendly Version 
February 06, 2018 - 4:02 p.m.
Gilead Sciences Announces 10 Percent Increase in First Quarter 2018 Dividend
Printer Friendly Version 
February 06, 2018 - 4:01 p.m.
Gilead Sciences Announces Fourth Quarter and Full Year 2017 Financial Results
Printer Friendly Version 
February 01, 2018 - 4:05 p.m.
Jacqueline K. Barton, Ph.D., Joins Gilead Sciences’ Board of Directors
Printer Friendly Version 
January 23, 2018 - 4:02 p.m.
Gilead Sciences to Release Fourth Quarter and Full Year 2017 Financial Results on Tuesday, February 6, 2018
Printer Friendly Version 
January 18, 2018 - 8:31 a.m.
Kite Announces Clinical Collaboration to Evaluate Investigational Combination of Yescarta™ (Axicabtagene Ciloleucel) and Pfizer’s Utomilumab in Large B-Cell Lymphoma
Printer Friendly Version 
NASDAQ (US Dollar)
$67.35
 Stock is Down 0.22 (0.33%)
Data as of 12/13/18 4:00 p.m. ET
Minimum 20 minute delay
Refresh Quote